Botensilimab

5 trials 3 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

4 Sponsors

6 Countries

Phase III

Phase II

Phase III: 1 Phase II: 4

Indications tested

Colon cancer metastatic 1 Gastric cancer 1 Colorectal adenocarcinoma 1

Sponsors using this IMP

Agenus Inc. 2 Centre Leon Berard 1 Fondazione GONO G.I. 1 Netherlands Cancer Institute 1

All trials

5 total

Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin… Recruiting

2023-506291-28-00 Phase III 1 country Centre Leon Berard
Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS) Recruiting

2023-505756-21-00 Phase II 1 country Netherlands Cancer Institute
Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting

2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga… Ended

2022-502065-23-00 Phase II 4 countries Agenus Inc.
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended

2022-500652-37-00 Phase II 5 countries Agenus Inc.

Showing 1–5 of 5 trials

← All drugs A–Z